米力农注射液治疗高血压性心脏病伴心力衰竭的临床观察

发布时间：2018-06-22 18:47

本文选题：米力农注射液 + 高血压性心脏病　；参考：《中国药房》2017年05期

【摘要】：目的:观察米力农注射液治疗高血压性心脏病伴心力衰竭的疗效及安全性。方法:将120例高血压性心脏病伴慢性心力衰竭患者按随机数字表法分为对照组与观察组,各60例。对照组患者接受常规治疗,包括控制血压、抗心力衰竭等对症处理;观察组患者在对照组基础上加用米力农注射液0.3 mg/kg,微量持续泵入,qd,连续5 d为1个疗程,每月治疗1个疗程,连续治疗6个月。两组患者均随访1年。观察两组患者治疗前,治疗3、6个月及治疗后1年6min步行距离(6MWD)、血浆脑钠肽(BNP)、左室射血分数(LVEF)、心脏指数(CI)、左室舒张末期内径(LVEDD)、静息心率、坐位收缩压、坐位舒张压、再住院、心血管病死发生情况,并比较两组患者心功能改善疗效及不良反应发生率。结果:治疗前,两组患者6MWD、BNP、LVEF、CI、LVEDD、静息心率、坐位收缩压、坐位舒张压比较,差异均无统计学意义(P0.05)。治疗3、6个月及治疗后1年,两组患者6MWD、LVEF、CI均显著上升,BNP、LVEDD、静息心率、坐位收缩压、坐位舒张压均显著下降,且观察组改善程度显著优于对照组,差异有统计学意义(P0.05)。观察组患者心功能改善总有效率为90.00%,显著高于对照组的63.33%,差异有统计学意义(P0.05)。随访1年,观察组患者再住院率显著低于对照组,差异有统计学意义(P0.05);心血管病死率比较,差异无统计学意义(P0.05)。两组患者不良反应发生率比较,差异无统计学意义(P0.05)。结论:米力农注射液治疗高血压性心脏病伴心力衰竭的疗效显著,能明显降低患者BNP和再住院率,改善预后,且安全性较好。
[Abstract]:Objective: to observe the efficacy and safety of milrinone injection in the treatment of hypertensive heart disease with heart failure. Methods: 120 patients with hypertensive heart disease complicated with chronic heart failure were randomly divided into control group and observation group with 60 cases each. The patients in the control group received routine treatment, including controlling blood pressure and anti-heart failure, the patients in the observation group were treated with milrinone injection of 0.3 mg / kg on the basis of the control group, and the patients in the observation group were continuously pumped into QD for 5 days as a course of treatment. One course of treatment was given each month for 6 months. The patients in both groups were followed up for 1 year. 6min walking distance (6MWD), plasma brain natriuretic peptide (BNP), left ventricular ejection fraction (LVEF), cardiac index (CI), left ventricular end-diastolic diameter (LVEDD), resting heart rate, sitting systolic pressure (SBP), sitting diastolic pressure (DBP), sitting diastolic blood pressure (SBP), sitting diastolic blood pressure (DBP), left ventricular end-diastolic diameter (LVEDD) were observed before and after treatment in both groups. The incidence of cardiovascular death and the improvement of cardiac function and the incidence of adverse reactions were compared between the two groups. Results: before treatment, there was no significant difference in 6MWDNPBNPLVEFCI-LVEDDD, resting heart rate, sitting systolic blood pressure and sitting diastolic blood pressure between the two groups (P0.05). After 3 months, 6 months and 1 year after treatment, 6MW DV LVEFV CI increased significantly in both groups. Resting heart rate, sitting systolic blood pressure and sitting diastolic pressure were significantly decreased in both groups, and the improvement in the observation group was significantly better than that in the control group (P0.05). The total effective rate of heart function improvement in the observation group was 90.00g, which was significantly higher than that in the control group (63.33), the difference was statistically significant (P0.05). Follow up for one year, the observation group patients re-hospitalization rate was significantly lower than the control group, the difference was statistically significant (P0.05), cardiovascular mortality, the difference was not statistically significant (P0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P0.05). Conclusion: milrinone injection is effective in the treatment of hypertensive heart disease with heart failure. It can significantly reduce BNP and rehospitalization rate, improve prognosis, and is safe.
【作者单位】：无锡市第三人民医院心血管内科;
【分类号】：R541.6;R541.3

【参考文献】